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Introduction. Acute adrenal crisis in relation to nasal steroid overuse has been reported very scantly in English medical
literature and remains an underdiagnosed condition. Case presentation. A 55 year-old male presented with altered mental status,
retrograde amnesia, ﬂuid refractory hypotension, abdominal pain, fever, and chest pain. Physical examination revealed amnesia,
bradypsychia, tachycardia, decreased muscle tone and hyporeﬂexia. Overuse of nasal steroid was suspected by history. Random
earlymorningcortisollevelwas<0.2mcg/dL.Thepatientwasstartedonhydrocortisoneandwithin24hourshehadafullrecovery.
Conclusion. This one-of-a-kind case describes acute adrenal crisis secondary to withdrawal from inhaled nasal corticosteroids
overuse in a patient with particular risk factors. Prevention and early recognition of this disorder can signiﬁcantly reduce its
morbidity and mortality.
1.Introduction
Every day, emergency departments face patients present-
ing with peripheral vascular collapse, shock, hypotension
refractory to ﬂuid replacement, change in mental status,
and/or fever. The diagnosis of acute adrenal crisis is not
typically considered, even when the patient is known to
haveadrenalinsuﬃciency(AI).Withoutappropriatetherapy,
it is a potential life-threatening disorder, which usually
progresses to coma and death.
2.CaseReport
A 55-year-old Caucasian male presented to the emergency
departmentwithalteredmentalstatus,generalizedweakness,
diarrhea, and vomiting. He had been in his usual state of
health the previous day, but when his wife returned from
an overnight trip, she found the patient in his current state
with signs of fecal and urinary incontinence. On arrival, the
patient had no signs of trauma, was lethargic with decreased
responsiveness, and was unable to recall recent events.
Thepatienthasalongstandinghistoryofseizuredisorder
and takes phenytoin and phenobarbital. Additional his-
tory includes hypothyroidism (diagnosed seven years ago),
hypercholesterolemia, osteoarthritis, and chronic knee pain.
He had craniotomy and brain tumor removal as a child
(presumably a meningioma), a recent arthrocentesis, and a
right hip replacement. The patient is listed as disabled due to
the chronic knee pain, does not smoke or use illicit drugs,
and occasionally consumes alcohol. He is known to suﬀer
from seasonal allergies and uses a nasal spray as needed.
Two weeks prior, the patient was diagnosed with rhinitis
medicamentosa and was prescribed ﬂuticasone propionate
(Fp) nasal spray one puﬀ BID.
3. Assessment
On physical examination, the patient was found to be
lethargic and having anterograde and retrograde amnesia,
but he was arousable. Heart rate was 100 beats/minute; his
bloodpressurewas90/60mmHg;andhisrespiratoryratewas
17 breaths/minute with room-air oxygen saturation of 98%.2 Case Reports in Medicine
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Figure 1: Pelvic/abdominal X-ray showing osteopenia.
He was disoriented and was found to have bradypsychia;
generalized decreased muscular tone and strength and deep
tendon reﬂexes were noted. The rest of his physical exami-
nation was unremarkable. Laboratory studies on admission
showed a WBC count of 4.3 × 103 cells/mm3, Hemoglobin
and Hematocrit of 11.4g/dL and 32.6%, respectively, and
platelet count of 132 × 103 cells/mm3. His liver function
test showed AST of 71U/L, alkaline phosphatase of 371U/L,
and GGTP of 275U/L; his cardiac enzymes revealed an
elevated CPK of 768U/L and CK-MB of 18.9U/L EKG
was normal. Basic metabolic panel revealed sodium level of
133mEq/L potassium of 3.4meq/L; his BUN and Creatinine
were 29mg/dL and 2.3mg/dL, respectively, and his Glucose
level was 89mg/dL. The urinalysis was positive for blood but
no cells were seen, and the toxicology screen was positive for
barbiturates. The patient’s TSH level was 0.162mU/L. At this
point, a diagnosis of altered mental status, gastroenteritis,
acute renal failure secondary to volume depletion, mild
rhabdomyolysis from prolonged recumbent position, and
a possible postictal state versus phenytoin intoxication was
made in this patient.
After IV hydration, he continued to be hypotensive,
lethargic, and disoriented but showed no evident ictal activ-
ity. Head CT reported craniectomy with encephalomalacia
in the right frontal lobe, but no acute pathology. Brain
MRI/MRA and EEG were ordered. Further laboratory results
revealedlowfreeT4,aCPKlevelthathadspikedto1506U/L,
BUN 13mg/dL, and creatinine 1.2mg/dL. His calcium was
6.5mg/dL, and albumin was 2.3g/dL. These electrolyte
abnormalities were corrected. Due to abdominal pain and
distention, an abdominal X-ray was ordered revealing a
nonspeciﬁcbowelgaspattern,moderatelefthipdegenerative
changes,osteopenicbonechanges,andrighthiparthroplasty
(Figure 1).
As the ﬁrst day continued, the patient developed new
onset atrial ﬁbrillation with RVR. He was started on digoxin
and heparin protocol. Blood cultures were negative and his
phenytoin level was relatively low at 7.1mg/L. Dopamine
infusion was required to maintain hemodynamic stability.
After reinterviewing the patient’s wife, it was learned that
Figure 2: Head CT showing encephalomalacia in the right frontal
lobe.
Figure 3: MRI of the brain showing no mass or enhancing lesion.
the patient had used his prescribed 2 bottles (approx. 16g
each) of nasal spray several times a day until he ran out of
medication 3 days prior to admission. It was at this point
that AI was suspected. A random early morning cortisol
level was ordered and the patient was started on 50mg of
Hydrocortisone intravenously every 8 hours (Figure 2).
On day 2, the random early morning cortisol level
was <0.2mcg/dL. Atrial ﬁbrillation was self-limited and
BP was improving. Digoxin was discontinued. The patient
had a WBC count of 2.4 × 103 cells/mm3, Hemoglobin
and Hematocrit of 10.6g/dL and 29.3%, respectively, and a
platelet countof 117×103 cells/mm3. Fecal occultblood test,
C. diﬃcile, and fecal leukocyte studies were negative, and
his diarrhea stopped. A 2D echocardiogram showed normal
ejection fraction. A nonenhanced MRI revealed a large area
of encephalomalacia in the right frontal lobe related to
previous craniotomy, with no acute underlying pathology
(Figure 3).
On day 3, the patient was showing good response to
treatment with full recovery of mental status; EEG displayed
encephalopathy with a right frontal epilectogenic focus.Case Reports in Medicine 3
Within 24 hours, his early morning cortisol level had
elevated to 50mcg/dL, his blood pressure stabilized at
110/70mmHg, and HR was 85 beats per minute. The
patient’s CBC had improved and the patient was afebrile;
intravenous ﬂuids were decreased. He was discharged home
two days after.
4. Discussion
Adrenal insuﬃciency (AI) is caused by insuﬃcient cortisol
secretion from the adrenal gland [1, 2]. Acute adrenal
crisis is usually diﬃcult to recognize clinically, presenting
most commonly as shock, but also as a collection of
nonspeciﬁc symptoms, and only about half of patients
with this condition have hypotension before development
of shock [3]. Other symptoms may include abdominal
tenderness, fever, nausea, vomiting, and neuropsychiatric
symptoms such as confusion or disorientation [1, 4, 5].
Abdominal rigidity or rebound tenderness may lead to the
incorrect diagnosis of an acute surgical abdomen [1, 5].
In most patients, hyponatremia and hyperkalemia are also
detected; our patient did not show high potassium levels,
probably due to gastrointestinal losses from diarrhea. This
was a complex case in which the etiology of the altered
mental status and hypotension was not clear because of the
concomitant existence of seizure disorder, volume depletion,
and a possible phenytoin overdose. The dramatic clinical
response to the hydrocortisone treatment clearly supported
the diagnosis of acute adrenal crisis caused by an acute
withdrawal from inhaled nasal corticosteroids (ICSs).
The widespread and habitual use of ICSs for the treat-
ment of asthma and allergic rhinitis may lead clinicians
to overlook and underdiagnosis of this condition. An
abrupt withdrawal of corticosteroids such as ﬂuticasone
may promote an adrenal crisis [1, 2]. While one test
revealed that “as little as 88mcg/day of ﬂuticasone can
produce 10% adrenal suppression,” another revealed that
“352mcg/day can produce 50% adrenal suppression” [5].
Since adrenal crisis has resulted in reported deaths and
intensive care cases, some researchers suggest that the
risks of prescribing ﬂuticasone, especially in doses above
352mcg/day, outweigh the possible beneﬁts [6, 7]. In this
case, the patient used 100mcg of ﬂuticasone an average of
22 times per day, which means that he received an average of
2200mcg/day.
There are few literature reports regarding this condition.
Todd et al. described AI in a 33-year-old male with diﬃcult-
to-controlasthmawhohadbeentaking1,000–2,000mcg/day
of Fp for 3 years [8]. In 2005, Licata described one patient
admitted to the hospital with symptoms of AI after overuse
of ﬂuticasone nasal spray [9]. In an observational study
investigating the prevalence and clinical presentation of AI
in patients who were prescribed ICSs by French physicians
during the period 2000–05, Molimard et al. identiﬁed forty-
six cases of AI, among which 23 cases presented with clinical
symptoms of AI alone and 23 with exogenous Cushing’s
syndrome. In 32 cases ICSs were prescribed at high doses;
ICS prescribed were Fp (n = 24), budesonide (n = 2),
and beclometasone dipropionate (n = 5) [10]. Indeed,
several studies that have looked at Hypothalamus-Pituitary-
Adrenal axis (HPA) suppression with ICS and meta-analysis
collecting these studies indicated that, overall, ICSs have a
minimal eﬀect on the HPA both in children and in adults,
so that there is no reason to perform routine monitoring of
adrenal function in patients treated with ICSs.
On the other hand, ﬂuticasone is known to have greater
dose-related systemic bioactivity compared with other avail-
able inhaled corticosteroids, particularly at doses above
800micg inhaled via pressurized metered-dose inhaler [11].
Some reviews and meta-analyses showed that there are few
studies performed with high doses of corticosteroids and
concludedthat,forroutineprescribingwithintheestablished
therapeutic dose-response range (50–500micg/day), ﬂutica-
sone has minimal eﬀects on adrenal function, while high-
dose, inhaled ﬂuticasone caused mild-to-signiﬁcant adrenal
suppression with a very variable interindividual clinical
response; this is probably related also to speciﬁc patient’s
comorbidities and conditions that may predispose to an
increased adrenal suppressant response [12, 13]. Fluticasone
has a delayed onset of action, with maximal beneﬁt taking
several days, and its oral bioavailability and GI absorption
are minimal (<1%) due to presystemic metabolism. Nasal
bioavailability is ≤2% and Oral inhalation ranges between
18% to 21%. Several randomized and pharmacodynamics
clinicaltrialshaveshownﬁndingsconsistentwithitsminimal
systemic availability, describing lack of signiﬁcant eﬀects on
hypothalamic-pituitary-adrenal axis function as assessed by
plasma cortisol and 24-hour urinary cortisol response to
the 6-hour cosyntropin stimulation test following intranasal
ﬂuticasone propionate at a dosage of up to 4mg/day
[14, 15]. These ﬁndings indicate that even though larger-
than-therapeutic dosages of ﬂuticasone were given, this
particular patient probably had a higher susceptibility to
develop adrenal suppression given his particular character-
istics.
5. Conclusion
AI related to inhaled nasal corticosteroid overuse in adults is
an overlooked phenomenon scantly described in the English
medical literature. This entity should be suspected in the
appropriate clinical scenario whenever patients experience
ﬂuid administration refractory shock, especially if we have
a history of abrupt withdrawal from glucocorticoid therapy,
either oral, systemic, or inhaled. This case also stresses the
importance of adequate patient education on medication
administration in order to prevent unexpected adverse
events.
Abbreviations
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